Ocular Therapeutix said Tuesday that its experimental treatment, called Axpaxli, maintained vision with less frequent injections compared to a standard treatment for patients with a common cause of age-related blindness — achieving the primary goal of a late-stage clinical trial.
However, the difference in the durability of treatment between Axpaxli and the active control in the study was narrower than investors expected — a finding that may spark debate about Axpaxli’s commercial potential in wet age-related macular degeneration, where effective drugs are already approved.
In the Phase 3 study, 74% and 66% of participants administered a single eye injection of Axpaxli maintained their vision for nine months and one year without further interventions compared to 56% and 44% of participants treated with a low dose of Eylea, an approved drug from Regeneron Pharma at the same time points, Ocular reported in a press release.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
Already have an account? Log in
First Appeared on
Source link
Leave feedback about this